Paper Details

  1. Home
  2. Paper Details

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.

Author: , CampbellPhilip, CarsonRobin, CavoMichele, ChiuChristopher, CookMark, CrepaldiAndre, CristWendy, DeraedtWilliam, DimopoulosMeletios A, DoyenChantal, FujisakiTomoaki, GargMamta, GrosickiSebastian, IosavaGenadi, JakubowiakAndrzej, KaplanPolina, KnopStefan, LiberatiAnna M, LucioPaulo, MateosMaría-Victoria, NagyZsolt, NguyenHuong, PourLudek, QiMing, San-MiguelJesus, ShelekhovaTatiana, SuzukiKenshi, WangJianping, YoonSung-Soo

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

A combination of bortezomib, melphalan, and prednisone is a standard treatment for newly diagnosed multiple myeloma in people who can't have a stem cell transplant. Daratumumab has shown effectiveness when added to standard treatments for people whose myeloma has returned or stopped responding to other treatments.
Paper Details　
Original Abstract of the Article :
The combination of bortezomib, melphalan, and prednisone is a standard treatment for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem-cell transplantation. Daratumumab has shown efficacy in combination with standard-of-care regimens in patients with relapsed or r...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1056/NEJMoa1714678

データ提供：米国国立医学図書館（NLM）

Daratumumab: A Powerful New Ally in the Fight Against Multiple Myeloma

Multiple myeloma, a cancer of plasma cells, can be a challenging disease to treat. This study, like a desert explorer venturing into unknown territory, explores the effectiveness of daratumumab, a new drug, in combination with standard-of-care treatments for multiple myeloma. The study found that daratumumab, when combined with bortezomib, melphalan, and prednisone, showed promising results in patients with newly diagnosed multiple myeloma who were not eligible for stem cell transplantation.

A New Approach to Myeloma Treatment

This study highlights the potential of daratumumab in combination with standard-of-care therapies for multiple myeloma. The results offer a new and promising approach to treating this complex disease, suggesting that daratumumab could become a valuable addition to the therapeutic arsenal. The findings, like a newly discovered oasis in the desert, bring hope for better treatment outcomes for patients with multiple myeloma.

A New Frontier in Myeloma Treatment

This study underscores the importance of ongoing research and development of new therapies for multiple myeloma. The discovery of daratumumab and its potential efficacy in combination with other treatments offer a new frontier in myeloma management. The study's findings, like a camel caravan navigating a vast desert, offer a promising path towards improved treatment options and better outcomes for patients.

Dr.Camel's Conclusion

This study offers a new and exciting approach to treating multiple myeloma, bringing hope for improved treatment outcomes for patients. The discovery of daratumumab and its potential efficacy in combination with other treatments is a significant breakthrough in the fight against this complex disease. This research, like a camel caravan discovering a new oasis, provides valuable insights into the future of myeloma treatment.

Date :
  1. Date Completed 2018-02-14
  2. Date Revised 2021-01-05
Further Info :

Pubmed ID

29231133

DOI: Digital Object Identifier

10.1056/NEJMoa1714678

Related Literature

Article Analysis
・Effective treatment of multiple myeloma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.